ALAnn M. Leen

Ann M. Leen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ann M. Leen has a total of 68 co-authors. Here are the top co-authors by number of shared publications:

  • Cliona M Rooney

    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children's Hospital, Houston, Texas, USA

    4 shared publications
  • Cliona M. Rooney

    Center for Cell and Gene Therapy and Departments of Pediatrics, Immunology, Medicine, and Virology, Baylor College of Medicine, Texas Children's Hospital and the Methodist Hospital, Houston

    3 shared publications
  • Helen E Heslop

    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children's Hospital, Houston, Texas, USA

    3 shared publications
  • Helen E. Heslop

    Center for Cell and Gene Therapy and Departments of Pediatrics, Immunology, Medicine, and Virology, Baylor College of Medicine, Texas Children's Hospital and the Methodist Hospital, Houston

    3 shared publications
  • Malcolm K Brenner

    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children's Hospital, Houston, Texas, USA

    3 shared publications
  • Adrian P. Gee

    Center for Cell and Gene Therapy and Departments of Pediatrics, Immunology, Medicine, and Virology, Baylor College of Medicine, Texas Children's Hospital and the Methodist Hospital, Houston

    2 shared publications

Latest Publications

  • Open Access

    451. Robust Manufacture of CAR-T Cells

    by Pradip Bajgain, John Wilson, Dan Welch, Helen E. Heslop, Cliona M. Rooney, Malcolm K. Brenner, Ann M. Leen, Juan F. Vera

  • Open Access

    751. Improving CAR T Cell Function by Reversing the Immunosuppressive Tumor Environment of Pancreatic Cancer

    by Sujita Sukumaran, Somala Mohammed, Norihiro Watanabe, Pradip Bajgain, Salma Ansari, Usanarat Anurathapan, Helen E. Heslop, Cliona R. Rooney, Malcolm K. Brenner, Ann M. Leen, et al.

  • Open Access

    Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections

    by Ulrike Gerdemann, Jacqueline M Keirnan, Usha L Katari, Ryu Yanagisawa, Anne S Christin, Leslie E Huye, Serena K Perna, Sravya Ennamuri, Stephen Gottschalk, Malcolm K Brenner, et al.


  • Open Access

    Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma

    by Ulrike Gerdemann, Usha Katari, Anne S Christin, Conrad R Cruz, Tamara Tripic, Alexandra Rousseau, Stephen M Gottschalk, Barbara Savoldo, Juan F Vera, Helen E Heslop, et al.


  • Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation

    by Ann M Leen, Tamara Tripic, Cliona M Rooney

    (2010). Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opinion on Biological Therapy: Vol. 10, No. 3, pp. 337-351.


  • Top Cited Papers
    Open Access

    Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation

    by Ann M. Leen, Anne Christin, Gary D. Myers, Hao Liu, Conrad R. Cruz, Patrick J. Hanley, Alana A. Kennedy-Nasser, Kathryn S. Leung, Adrian P. Gee, Robert A. Krance, et al.

    Viral infection or reactivation remains a major cause of morbidity and mortality after allogeneic stem cell transplantation. We now show that infusions of single cytotoxic T lymphocyte (CTL) lines (5 × 106-1.35 × 108 cells/m2) with specificity for 2 commonly detected viruses, Epstein-Barr virus (EBV) and adenovirus, can be safely administered to pediatric transplantation recipients receiving partially human leukocyte antigen–matched and haploidentical stem cell grafts (n = 13), without inducing graft-versus-host disease. The EBV-specific component of the CTLs expanded in vivo and persisted for more than 12 weeks, but the adenovirus-specific component only expanded in vivo in the presence of concomitant adenoviral infection. Nevertheless, adenovirus-specific T cells could be detected for at least 8 weeks in peripheral blood, even in CTL recipients without viral infection, provided the adenovirus-specific component of their circulating lymphocytes was first expanded by exposure to adenoviral antigens ex vivo. After infusion, none of these 13 high-risk recipients developed EBV-associated lymphoproliferative disease, while 2 of the subjects had resolution of their adenoviral disease. Hence, bispecific CTLs containing both EBV- and adenovirus-specific T cells can safely reconstitute an antigen responsive “memory” population of CTLs after human leukocyte antigen–mismatched stem cell transplantation and may provide antiviral activity. This trial was registered at www.clinicaltrials.gov as #NCT00590083.


  • Open Access

    Cytotoxic T lymphocytes as immune‐therapy in haematological practice

    by Ann M. Leen, Helen E. Heslop

    Viral infections are a significant cause of morbidity and mortality, particularly in pediatric allogeneic haematopoietic stem cell transplant recipients. Effective therapies are limited and often associated with significant side effects. Adoptive transfer of virus‐reactive T cells offers a means of reconstituting antiviral immunity and this approach has been successfully used to prevent and treat cytomegalovirus, Epstein‐Barr virus, and adenovirus infections in vivo. This review outlines the clinical trials that have been performed to date, and will describe future initiatives to (a) develop strategies that can increase the breadth of the viruses that can be targeted, and (b) simplify the process to extend this technology to more centers so that cellular therapy to reconstitute immunity can be more widely applied.


  • Using Dendritic Cell Maturation and IL-12 Producing Capacity as Markers of Function: A Cautionary Tale

    by Anjum S. Kaka, Aaron E. Foster, Heidi L. Weiss, Cliona M. Rooney, Ann M. Leen

    Effective dendritic cell (DC) function depends on sufficient expression of antigen and costimulatory molecules, and secretion of interleukin (IL)-12. We sought to augment DC stimulatory capacity by optimizing DC phenotype and IL-12 production. DCs, obtained by CD14-selection, were matured using 8 different cytokine cocktails, and expression of costimulatory/major histocompatibility complex molecules and IL-12 production at the end of maturation was assessed. DC stimulatory capacity was determined after pulsing with immunogenic adenoviral CD8+ peptide epitopes or after transduction with an Ad5f35-null vector. Resultant T-cell cultures were analyzed using pentamer and interferon-γ enzyme-linked immunosorbent spot assays. On the basis of DC expression of maturation markers and IL-12 production, we defined prototype “minimal” [tumor necrosis factor-α (TNF-α), prostaglandin E2], “standard” (IL-1, IL-6, TNF-α, prostaglandin E2), and “optimal” (IL-1, IL-6, TNF-α, interferon-α, CD40 ligand) DC cocktails. Optimal DCs were functionally superior when pulsed with CD8+ peptides, but when transduced with Ad5f35, functioned poorly as antigen-presenting cells. We investigated the mechanisms underlying this discrepancy and suggest that prolonged stimulation with potent cytokines (optimal cocktail) in combination with adenoviral transduction alters the kinetics of DC maturation such that the DCs are functionally exhausted by the traditional 48-hour maturation time point. Shortening the DC maturation period posttransduction restored optimal DC stimulatory capacity. Thus, maturation stimuli and viral transduction affects DC phenotype, IL-12 producing capacity, and kinetics of maturation, and all must be considered before designing protocols to generate the optimal DC for cytotoxic T lymphocyte generation.


  • Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy

    by Ann M. Leen, Anne Christin, Mariam Khalil, Heidi Weiss, Adrian P. Gee, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney, Catherine M. Bollard

    Adenoviral infections in the immunocompromised host are associated with significant morbidity and mortality. Although the adoptive transfer of adenovirus-specific T cells may prevent and treat such infections, the T-cell immune response to the multiplicity of adenovirus serotypes and subspecies that infect humans has not been well characterized, impeding the development of such approaches. We have, therefore, analyzed the specificities of T-cell responses to the viral capsid hexon antigen, since this structure is highly conserved in human pathogens. We screened 25 human cytotoxic T-cell lines with adenovirus specificity to extensively characterize their responses to adenoviral hexon and to identify a panel of novel CD4+and CD8+T-cell epitopes. Using a peptide library spanning the entire sequence of the hexon protein, we confirmed the responsiveness of these cytotoxic T-cell lines to seven peptides described previously and also identified 33 new CD4- or CD8-restricted hexon epitopes. Importantly, the majority of these epitopes were shared among different adenovirus subspecies, suggesting that T cells with such specificities could recognize and be protective against multiple serotypes, simplifying the task of effective adoptive transfer or vaccine-based immunotherapy for treating infection by this virus.


  • Adoptive immunotherapy for herpesviruses

    by Ann M. Leen, Uluhan Sili, Catherine M. Bollard, Cliona M. Rooney

    Introduction Herpesvirus infections rarely cause significant problems in the immunocompetent human host. However, in the immunosuppressed, for example, recipients of hematopoietic stem cell transplants (HSCT) (Rooney et al., 1998), solid organ transplants (SOT), or human immunodeficiency virus (HIV)-infected individuals, viral infections/reactivations are common and are associated with considerable morbidity and mortality. The resultant uncontrolled infections correlate with a lack of cellular immunity against viral antigens (Weinberg et al., 2001). While effective antiviral drugs are available for the treatment of some herpesvirus infections, adoptive immunotherapy, which is the artificial reconstitution of virus-specific T-cells with in vitro expanded cytotoxic T-lymphocytes (CTLs), for the prophylaxis and/or treatment of herpesviruses is an attractive option. The γ-herpesvirus, Epstein–Barr virus (EBV) is also associated with a heterogeneous range of malignancies and diseases that occur in apparently immunocompetent individuals and since these malignancies also express “foreign” viral antigenic targets they may also be good candidates for immunotherapy (Rickinson and Kieff, 2001). The advances in such adopt ive immunotherapeutic approaches will be discussed in this chapter. Therapy for herpesvirus-related infections and diseases Infectious complications relating to herpes simplex virus (HSV), varicella zoster virus (VZV) (Asanuma et al., 2000), Kaposi's sarcoma virus (KSV) (Wang et al., 2000), human herpesvirus (HHV)-6, -7 (Clark, 2002; Clark et al., 2003; Clark and Griffiths, 2003), cytomegalovirus (CMV) (Michaelides et al., 2002) and EBV (Heslop et al., 1994) are common in immunocompromised individuals.